Foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin

ABSTRACT

The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active ingredients for the treatment of human skin, especially in the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis, as well as for prophylactic and/or cosmetic purposes.

BACKGROUND AND STATE OF THE ART

This application claims the priority according to the Paris Conventionof the European Patent application EP 0802233.2 (filing date: Dec. 23,2008) as well as all benefits from earlier US application ser. no.61/140,152 (filing date: Dec. 23, 2008), which are both incorporatedherein by reference.

A number of foamable compositions containing pharmaceutically activeingredients is known in the art for the treatment of various medicalconditions of the skin or of body cavities. The state of the artincludes WO 2005/018530, WO 2008/038140, US 2008/044444, US 2006/275218,US 2007/020213, US 2002/001599, WO 2004/037225, WO 2005/011567, US2005/0232869, US 2005/0069566, and others, which are all incorporatedherein by reference. These foamable compositions and foam carriers havebeen developed as they can contain a number of pharmaceuticalingredients for the treatment of a variety of diseases of the skin or ofbody cavities. These foams are easy to apply to the skin and do avoidstinging and drying, properties that have been reported from previousfoam compositions. However, all of these compositions do require thepresence of one or more pharmaceutically active agents such asanti-inflammatory agents (e.g. COX-1 inhibitors, COX-2 inhibitors,salicylic acid derivatives, dicarboxylic acids or dicarboxylic acidderivatives, THF-α agents, immunosupressant agents, immunoregulatingagents, glucocorticoids, steroids or others). It is needless to statethat the need for pharmaceutically active agents is a disadvantage, assuch agents may have unwanted side effects at least with some of thepatients.

General Description of the Invention

It has now been found, that surprisingly a foamable composition which isessentially free of pharmaceutically active ingredients, consisting of

-   -   (a) at least one emollient,    -   (b) at least one stabilizer,    -   (c) at least one preservative,    -   (d) at least one emulsifier,    -   (e) at least one foam stabilizer,    -   (f) at least one moisturizer    -   together with a propellant,        can be used for the treatment of human skin especially for the        treatment of rosacea, acne, atopic dermatitis, contact        dermatitis, perioral dermatitis, psoriasis or neurodermitis.

A preferred embodiment of the invention is the use of a foamablecomposition essentially free of pharmaceutically active ingredients asdescribed before, wherein

-   -   (a) at least one emollient is caprylic/capric triglyceride,    -   (b) at least one stabilizer cetostearyl alcohol or glyceryl        stearate or a mixture thereof,    -   (c) at least one preservative is benzoic acid,    -   (d) at least one emulsifier is PEG-40 stearate, polysorbate 80        or a mixture thereof,    -   (e) at least one foam stabilizer is methylcellulose, xanthan gum        or a mixture thereof,    -   (f) at least one moisturizer is dimethyl isosorbide, propylene        glycol or a mixture thereof        together with a propellant for the treatment of human skin        especially for the treatment of rosacea, acne, atopic        dermatitis, contact dermatitis, perioral dermatitis, psoriasis        or neurodermitis.

An especially preferred embodiment of the invention is the use of afoamable composition essentially free of pharmaceutically activeingredients as described before, containing

-   -   (a) caprylic/capric triglyceride in an amount of about 10.87        weight percent,    -   (b) a mixture of about 1.09 weight percent cetostearyl alcohol        and about 0.54 weight percent glyceryl stearate,    -   (c) benzoic acid in an amount of at least one preservative is        about 0.1 weight percent,    -   (d) a mixture of about 2.83 weight percent PEG-40 stearate and        about 0.98 weight percent polysorbate 80,    -   (e) a mixture of about 0.11 weight percent methylcellulose and        about 0.27 weight percent xanthan gum,    -   (f) a mixture of about 5.44 weight percent dimethyl isosorbide        and about 10.87 weight percent propylene glycol        together with a propellant for the treatment of human skin        especially for the treatment of rosacea, acne, atopic        dermatitis, contact dermatitis, perioral dermatitis, psoriasis        or neurodermitis.

As propellant a compound may be used, which is a gas at room temperatureunder normal pressure and which may be liquidified at increased pressureat room temperature. Useful propellants are butane, propane, isobutene,dimethylether, fluorocarbon gases or mixtures thereof.

The term “pharmaceutically active compounds” or “pharmaceutically activeingredients” refers to compounds with proved pharmaceutical activitydemonstrated in clinical trials and approved as a drug by the EuropeanMedicines Agency (EMEA) or the US Food and Drug Administration (FDA).The term “essentially free of pharmaceutically active compounds” or“essentially free of pharmaceutically active ingredients” means that no“pharmaceutically active compound” or “pharmaceutically activeingredient” has been intended to be added to the composition. The totalamount of pharmaceutically active ingredients as a result of unintendedcontamination is therefore well below 0.05%, preferably below 0.01%.Most preferred is a composition in which no amount of any pharmaceuticalingredient can be detected with standard analytical methods used inpharmaceutical technology.

The foamable compositions according to the invention are manufacturedaccording to the methods described in the art which are known to apharmaceutical expert. They are usually packed in a container with anoutlet valve. Possible containers in valves are likewise described inthe art and do not need to be explained in this document.

The foamable composition is substantially alcohol-free, i.e., free ofshort chain alcohols (with 1-4 carbon atoms chain length).

One known disadvantage of state of the art compositions is the lowsolubility of the pharmaceutically active compounds. It is therefore anadvantage of the compositions according to the present inventions thatthere is no need to solve any pharmaceutically active compounds.

In clinical tests it has been shown that foamable compositions accordingto the description provided herein have beneficial properties,especially in the treatment of rosacea. It was very surprising to notethat this therapeutic effect has been achieved without application ofany pharmaceutically active ingredient. A number of further medicalconditions can be treated with the composition according to the presentinvention such as acne, atopic dermatitis, contact dermatitis, perioraldermatitis, psoriasis and neurodermitis.

Furthermore the compositions described herein may be used for aprophylactic treatment of the human skin (e.g. in patients with a knowntendency to develop such disease).

The foamable composition compositions according to the descriptionprovided herein may also be used for a cosmetic treatment of the humanskin.

It is therefore another aspect of the invention to provide a method oftreating human skin disorders such as acne, atopic dermatitis, contactdermatitis, perioral dermatitis, psoriasis and neurodermitis by topicalapplication of a foam as described herein to a patient in need thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts investigators Global Assessment (IGA) scores for a foamcomposition according to the invention before and after treatment.

FIG. 2 depicts investigators Global Assessment (IGA) scores for acomparison foam composition before and after treatment.

FIG. 3 depicts an investigators telangiectasia assessment after a 12week study.

FIG. 4 compares a prior art composition to a composition according tothe present Invention.

It is a further aspect of the invention to provide a method ofprophylactic treatment of human skin, especially for humans with a knowntendency to develop skin disorders such as acne, atopic dermatitis,contact dermatitis, perioral dermatitis, psoriasis and neurodermitis bytopical application of a foam as described herein to such human.

It is a still further aspect of the invention to provide a method ofcosmetic treatment of human skin by topical application of a foam asdescribed herein to a human. For all of these applications describedherein (therapeutic, prophylactic or cosmetic) the followingcompositions essentially free of active pharmaceutical compounds packedin a container with an outlet valve have been found to be most useful

10.00-12.00 g/100 g  Caprylic/capric triglyceride 0.90-1.20 g/100 gCetostearyl alcohol 0.44-0.70 g/100 g Glyceryl stearate 0.10-0.15 g/100g Benzoic acid 2.50-3.00 g/100 g PEG-40 stearate 0.08-0.20 g/100 gMethylcellulose 0.20-0.32 g/100 g Xanthan gum 0.90-1.20 g/100 gPolysorbate 80 5.35-6.00 g/100 g Dimethyl isosorbide 10.87-12.25 g/100g  Propylene glycol to pH 4.5 Sodium hydroxide ad 100 Purified water7.00-9.00 g Propellant blend

EXAMPLES

Example 1

The following compositions are prepared according to methods known inthe art.

[g/100 g] [g/100 g] [g/100 g] [g/100 g] [g/100 g] Ingredient Function AB C D E Caprylic/capric Emollient 10.00 10.87 11.10 12.00 11.50triglyceride Cetostearyl alcohol Stabilizer 1.20 1.09 0.90 1.00 1.20Glyceryl stearate Stabilizer 0.44 0.54 0.60 0.55 0.70 Benzoic acidPreservative 0.10 0.10 0.11 0.12 0.15 PEG-40 stearate Emulsifier 3.002.83 2.50 2.60 2.95 Methylcellulose Foam 0.08 0.11 0.15 0.18 0.20stabilizer Xanthan gum Foam 0.20 0.27 0.25 0.30 0.32 stabilizerPolysorbate 80 Emulsifier 1.00 0.98 0.90 0.95 1.20 Dimethyl isosorbideMoisturizer 5.35 5.44 5.75 6.00 5.90 Propylene glycol Moisturizer 12.0010.87 11.80 12.25 11.50 Sodium hydroxide Neutralizer to pH 4.5 to pH 4.5to pH 4.5 to pH 4.5 to pH 4.5 Purified water External phase ad 100 ad100 ad 100 ad 100 ad 100 100.00 100.00 100.00 100.00 100.00 Propellantblend Foaming aid 8.00 8.00 7.00 9.00 8.50 Total 108.00 108.00 107.00109.00 108.50

The composition according to example 1B shows the most beneficialproperties.

Example 2

Patients suffering from rosacea are treated with the compositionsdescribed in example 1. The particular composition is applied severaltimes a day, preferably at least three times a day. After two weeks ofapplication patients show significantly less symptoms of rosacea. Thesymptoms are further decreasing over time upon continuation of theapplication as described above. Especially patients with mild forms ofrosacea do benefit from the application

Example 3

Patients suffering from psoriasis are treated with the compositionaccording to the invention. The composition is applied several times aday, preferably at least three times a day. After two weeks ofapplication patients show significantly less symptoms of psoriasis. Thesymptoms are further decreasing over time upon continuation of theapplication as described above.

Example 4

The use of the compositions according to example 1 has been compared toa prior art disclosure and the following data have been collected. It isbelieved that document US 2008/044444 is the closest prior art. Example9 of US 2008/044444 discloses a dicarboxylic acid composition which iscomparable to the composition of claim 1 but contains 15% azelaic acid.Azelaic acid is known to be effective in rosacea treatment. It is e.g.part of a gel formulation sold under the trademarks Finacea® andSkinoren Gel® and approved by various regulatory authorities includingthe FDA. Azelaic acid compositions such as Finacea are thereforeconsidered as a standard therapy in the treatment of rosacea. US2008/044444 describes quite a number of disorders treatable with thecompositions of US 2008/044444 (see paragraph [0186]). There is,however, no specific data proving effectiveness of such composition inthe treatment of any of the mentioned disorders.

The applicant has carried out clinical investigations comparing acomposition as described herein with a prior art composition asdescribed in example 9 of US 2008/044444. An azelaic acid containingfoam composition according to example 9 of US 2008/044444 (hereinafterreferred to as “Aza foam”) has been studied in a 12 week exploratory,multicenter, double-blind study compared with a composition according toexample 1b of the present application free of any pharmaceuticallyactive ingredient. More than 80 patients have been treated:approximately 50% with the azelaic acid containing foam (Aza foam), theother 50% with the foam composition according to example 1b. Thementioned patients have been treated twice daily over 12 weekstopically. The results are presented in the annexed figures:

FIGS. 1 and 2 show Investigators Global Assessment (IGA) scores for thetwo compositions before and after treatment demonstrating the assessedsevereness of the disease. The clinical investigators had to score thesevereness of papulopustular rosacea before and after treatment. FIG. 1shows the IGA score of the composition according to the invention, FIG.2 the IGA score of the composition according to Example 9 of US2008/044444. All data are provided as percentage of treated patients.FIGS. 1 and 2 indicate a comparable efficacy of both compositions: Ithas been found that a number of patients suffering from moderate tosevere forms of papulopustular rosacea prior to treatment shifted toclear to mild forms. No statistically significant difference between thetreatments has been found. This finding is surprising to the experts asazelaic acid is a well-recognized drug and a standard therapy in thetreatment of rosacea. It was therefore quite surprising that a foamablecomposition according to example 1 of the present application free ofazelaic acid shows comparable results.

Furthermore, a telangiectasia score has been measured duringexamination. Investigators have been asked to compare in the samerandomized double-blind study the severeness telangiectasia intensity.At the end of the 12-weeks period the investigators have been asked toassess if the patients telangiectasia intensity had been improved,remained unchanged or worsened. The results are presented in FIG. 3. Itis very surprising to note that the number of patients with improvedtelangiectasia score is much higher compared to treatment with theazelaic acid containing foam.

Furthermore, the number of adverse events (such as itching, stinging andburning) had been counted. Only mild or moderate adverse events havebeen reported, no serious adverse event had been reported during thisclinical study. As demonstrated in FIG. 4, the total number of adverseevents is significantly higher in the prior art composition comparing tothe composition according to the invention.

1. A method for applying a cosmetic product to the skin, comprisingtopically Use of a foamable composition essentially free ofpharmaceutically active ingredients, consisting of: 10.00-12.00 g/100 g Caprylic/capric triglyceride 0.90-1.20 g/100 g Cetostearyl alcohol0.44-0.70 g/100 g Glyceryl stearate 0.10-0.15 g/100 g Benzoic acid2.50-3.00 g/100 g PEG-40 stearate 0.08-0.20 g/100 g Methylcellulose0.20-0.32 g/100 g Xanthan gum 0.90-1.20 g/100 g Polysorbate 80 5.35-6.00g/100 g Dimethyl isosorbide 10.87-12.25 g/100 g  Propylene glycol to pH4.5 Sodium hydroxide ad 100 Purified water 7.00-9.00 g Propellant blend

in a container with an outlet valve.
 2. A method a foamable compositionessentially free of pharmaceutically active ingredients according toclaim 1, wherein said foamable composition consists of 10.00 g/100 g Caprylic/capric triglyceride 1.20 g/100 g Cetostearyl alcohol 0.44 g/100g Glyceryl stearate 0.10 g/100 g Benzoic acid 3.00 g/100 g PEG-40stearate 0.08 g/100 g Methylcellulose 0.20 g/100 g Xanthan gum 1.00g/100 g Polysorbate 80 5.35 g/100 g Dimethyl isosorbide 12.00 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad 100 Purified water 8.00 gPropellant blend

or consists of 10.87 g/100 g  Caprylic/capric triglyceride 1.09 g/100 gCetostearyl alcohol 0.54 g/100 g Glyceryl stearate 0.10 g/100 g Benzoicacid 2.83 g/100 g PEG-40 stearate 0.11 g/100 g Methylcellulose 0.27g/100 g Xanthan gum 0.98 g/100 g Polysorbate 80 5.44 g/100 g Dimethylisosorbide 10.87 g/100 g  Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.00 g Propellant blend

or consists of 11.10 g/100 g  Caprylic/capric triglyceride 0.90 g/100 gCetostearyl alcohol 0.60 g/100 g Glyceryl stearate 0.11 g/100 g Benzoicacid 2.50 g/100 g PEG-40 stearate 0.15 g/100 g Methylcellulose 0.25g/100 g Xanthan gum 0.90 g/100 g Polysorbate 80 5.75 g/100 g Dimethylisosorbide 11.80 g/100 g  Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 7.00 g Propellant blend

or consists of 12.00 g/100 g  Caprylic/capric triglyceride 1.00 g/100 gCetostearyl alcohol 0.55 g/100 g Glyceryl stearate 0.12 g/100 g Benzoicacid 2.60 g/100 g PEG-40 stearate 0.18 g/100 g Methylcellulose 0.30g/100 g Xanthan gum 0.95 g/100 g Polysorbate 80 6.00 g/100 g Dimethylisosorbide 12.25 g/100 g  Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 9.00 g Propellant blend

or consists of 11.50 g/100 g  Caprylic/capric triglyceride 1.20 g/100 gCetostearyl alcohol 0.70 g/100 g Glyceryl stearate 0.15 g/100 g Benzoicacid 2.95 g/100 g PEG-40 stearate 0.20 g/100 g Methylcellulose 0.32g/100 g Xanthan gum 1.20 g/100 g Polysorbate 80 5.90 g/100 g Dimethylisosorbide 11.50 g/100 g  Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.50 g Propellant blend


3. A method according to claim 1, wherein the propellant is butane,propane, isobutene, dimethylether, fluorocarbon gases or a mixturethereof. 4 A container with an outlet valve filled with a foamablecomposition essentially free of pharmaceutically active ingredients,said foamable composition consisting of: 10.00-12.00 g/100 g Caprylic/capric triglyceride 0.90-1.20 g/100 g Cetostearyl alcohol0.44-0.70 g/100 g Glyceryl stearate 0.10-0.15 g/100 g Benzoic acid2.50-3.00 g/100 g PEG-40 stearate 0.08-0.20 g/100 g Methylcellulose0.20-0.32 g/100 g Xanthan gum 0.90-1.20 g/100 g Polysorbate 80 5.35-6.00g/100 g Dimethyl isosorbide 10.87-12.25 g/100 g  Propylene glycol to pH4.5 Sodium hydroxide ad 100 Purified water 7.00-9.00 g Propellant blend


5. A container according to claim 4, wherein said foamable compositionconsists of 10.00 g/100 g Caprylic/capric triglyceride 1.20 g/100 gCetostearyl alcohol 0.44 g/100 g Glyceryl stearate 0.10 g/100 g Benzoicacid 3.00 g/100 g PEG-40 stearate 0.08 g/100 g Methylcellulose 0.20g/100 g Xanthan gum 1.00 g/100 g Polysorbate 80 5.35 g/100 g Dimethylisosorbide 12.00 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.00 g Propellant blend

or consists of 10.87 g/100 g Caprylic/capric triglyceride 1.09 g/100 gCetostearyl alcohol 0.54 g/100 g Glyceryl stearate 0.10 g/100 g Benzoicacid 2.83 g/100 g PEG-40 stearate 0.11 g/100 g Methylcellulose 0.27g/100 g Xanthan gum 0.98 g/100 g Polysorbate 80 5.44 g/100 g Dimethylisosorbide 10.87 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.00 g Propellant blend

or consists of 11.10 g/100 g Caprylic/capric triglyceride 0.90 g/100 gCetostearyl alcohol 0.60 g/100 g Glyceryl stearate 0.11 g/100 g Benzoicacid 2.50 g/100 g PEG-40 stearate 0.15 g/100 g Methylcellulose 0.25g/100 g Xanthan gum 0.90 g/100 g Polysorbate 80 5.75 g/100 g Dimethylisosorbide 11.80 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 7.00 g Propellant blend

or consists of 12.00 g/100 g Caprylic/capric triglyceride 1.00 g/100 gCetostearyl alcohol 0.55 g/100 g Glyceryl stearate 0.12 g/100 g Benzoicacid 2.60 g/100 g PEG-40 stearate 0.18 g/100 g Methylcellulose 0.30g/100 g Xanthan gum 0.95 g/100 g Polysorbate 80 6.00 g/100 g Dimethylisosorbide 12.25 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 9.00 g Propellant blend

or consists of 11.50 g/100 g Caprylic/capric triglyceride 1.20 g/100 gCetostearyl alcohol 0.70 g/100 g Glyceryl stearate 0.15 g/100 g Benzoicacid 2.95 g/100 g PEG-40 stearate 0.20 g/100 g Methylcellulose 0.32g/100 g Xanthan gum 1.20 g/100 g Polysorbate 80 5.90 g/100 g Dimethylisosorbide 11.50 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.50 g Propellant blend.


6. A container according to claim 4, wherein the propellant is butane,propane, isobutene, dimethylether, fluorocarbon gases or a mixturethereof.
 7. A method according to claim 2, wherein the propellant isbutane, propane, isobutene, dimethylether, fluorocarbon gases or amixture thereof.
 8. A container according to claim 5, wherein thepropellant is butane, propane, isobutene, dimethylether, fluorocarbongases or a mixture thereof.
 9. A method according to claim 2, whereinsaid foamable composition consists of 10.00 g/100 g Caprylic/caprictriglyceride 1.20 g/100 g Cetostearyl alcohol 0.44 g/100 g Glycerylstearate 0.10 g/100 g Benzoic acid 3.00 g/100 g PEG-40 stearate 0.08g/100 g Methylcellulose 0.20 g/100 g Xanthan gum 1.00 g/100 gPolysorbate 80 5.35 g/100 g Dimethyl isosorbide 12.00 g/100 g Propyleneglycol to pH 4.5 Sodium hydroxide ad 100 Purified water 8.00 gPropellant blend.


10. A method according to claim 2, wherein said foamable compositionconsists of 10.87 g/100 g Caprylic/capric triglyceride 1.09 g/100 gCetostearyl alcohol 0.54 g/100 g Glyceryl stearate 0.10 g/100 g Benzoicacid 2.83 g/100 g PEG-40 stearate 0.11 g/100 g Methylcellulose 0.27g/100 g Xanthan gum 0.98 g/100 g Polysorbate 80 5.44 g/100 g Dimethylisosorbide 10.87 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.00 g Propellant blend.


11. A method according to claim 2, wherein said foamable compositionconsists of 11.10 g/100 g Caprylic/capric triglyceride 0.90 g/100 gCetostearyl alcohol 0.60 g/100 g Glyceryl stearate 0.11 g/100 g Benzoicacid 2.50 g/100 g PEG-40 stearate 0.15 g/100 g Methylcellulose 0.25g/100 g Xanthan gum 0.90 g/100 g Polysorbate 80 5.75 g/100 g Dimethylisosorbide 11.80 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 7.00 g Propellant blend.


12. A method according to claim 2, wherein said foamable compositionconsists of 12.00 g/100 g Caprylic/capric triglyceride 1.00 g/100 gCetostearyl alcohol 0.55 g/100 g Glyceryl stearate 0.12 g/100 g Benzoicacid 2.60 g/100 g PEG-40 stearate 0.18 g/100 g Methylcellulose 0.30g/100 g Xanthan gum 0.95 g/100 g Polysorbate 80 6.00 g/100 g Dimethylisosorbide 12.25 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 9.00 g Propellant blend.


13. A method according to claim 2, wherein said foamable compositionconsists of 11.50 g/100 g Caprylic/capric triglyceride 1.20 g/100 gCetostearyl alcohol 0.70 g/100 g Glyceryl stearate 0.15 g/100 g Benzoicacid 2.95 g/100 g PEG-40 stearate 0.20 g/100 g Methylcellulose 0.32g/100 g Xanthan gum 1.20 g/100 g Polysorbate 80 5.90 g/100 g Dimethylisosorbide 11.50 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.50 g Propellant blend.


14. A container according to claim 5, wherein said foamable compositionconsists of 10.00 g/100 g Caprylic/capric triglyceride 1.20 g/100 gCetostearyl alcohol 0.44 g/100 g Glyceryl stearate 0.10 g/100 g Benzoicacid 3.00 g/100 g PEG-40 stearate 0.08 g/100 g Methylcellulose 0.20g/100 g Xanthan gum 1.00 g/100 g Polysorbate 80 5.35 g/100 g Dimethylisosorbide 12.00 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.00 g Propellant blend.


15. A container according to claim 5, wherein said foamable compositionconsists of 10.87 g/100 g Caprylic/capric triglyceride 1.09 g/100 gCetostearyl alcohol 0.54 g/100 g Glyceryl stearate 0.10 g/100 g Benzoicacid 2.83 g/100 g PEG-40 stearate 0.11 g/100 g Methylcellulose 0.27g/100 g Xanthan gum 0.98 g/100 g Polysorbate 80 5.44 g/100 g Dimethylisosorbide 10.87 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.00 g Propellant blend.


16. A container according to claim 5, wherein said foamable compositionconsists of 11.10 g/100 g Caprylic/capric triglyceride 0.90 g/100 gCetostearyl alcohol 0.60 g/100 g Glyceryl stearate 0.11 g/100 g Benzoicacid 2.50 g/100 g PEG-40 stearate 0.15 g/100 g Methylcellulose 0.25g/100 g Xanthan gum 0.90 g/100 g Polysorbate 80 5.75 g/100 g Dimethylisosorbide 11.80 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 7.00 g Propellant blend.


17. A container according to claim 5, wherein said foamable compositionconsists of 12.00 g/100 g Caprylic/capric triglyceride 1.00 g/100 gCetostearyl alcohol 0.55 g/100 g Glyceryl stearate 0.12 g/100 g Benzoicacid 2.60 g/100 g PEG-40 stearate 0.18 g/100 g Methylcellulose 0.30g/100 g Xanthan gum 0.95 g/100 g Polysorbate 80 6.00 g/100 g Dimethylisosorbide 12.25 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 9.00 g Propellant blend.


18. A container according to claim 5, wherein said foamable compositionconsists of 11.50 g/100 g Caprylic/capric triglyceride 1.20 g/100 gCetostearyl alcohol 0.70 g/100 g Glyceryl stearate 0.15 g/100 g Benzoicacid 2.95 g/100 g PEG-40 stearate 0.20 g/100 g Methylcellulose 0,32g/100 g Xanthan gum 1.20 g/100 g Polysorbate 80 5.90 g/100 g Dimethylisosorbide 11.50 g/100 g Propylene glycol to pH 4.5 Sodium hydroxide ad100 Purified water 8.50 g Propellant blend.